Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 公共衛生學院
  3. 公共衛生碩士學位學程
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89816
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor陳秀熙zh_TW
dc.contributor.advisorHsiu-Hsi Chenen
dc.contributor.author蔡宇勛zh_TW
dc.contributor.authorYu-Hsun Tsaien
dc.date.accessioned2023-09-22T16:14:31Z-
dc.date.available2023-11-09-
dc.date.copyright2023-09-22-
dc.date.issued2023-
dc.date.submitted2023-08-08-
dc.identifier.citation1.John's Hopkins CSSE (2021): Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html.
2.Cao, W., et al. (2021). "Important factors affecting COVID-19 transmission and fatality in metropolises." Public health 190: e21.
3.Chiu, W.-T., et al. (2020). Determinants of Taiwan’s early containment of COVID-19 incidence, American Public Health Association. 110: 943-944.
4.洪敏元&洪慈穗 (2021). "淺談新型冠狀病毒 (COVID-19)." 華醫學報(55): 53-64.
5.R. Cohen, et al. (2021) "Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? " Infectious Diseases Now 2021 Vol. 51 Issue 5 Pages 418-423
6.柯獻欽, et al. (2020). "新冠肺炎病毒之群體免疫, 疫苗研發與卡介苗功效." 內科學誌 31(4): 254-261.
7.C.-Y. Hsu, J.-C. Chang, S. L.-S. Chen, H.-H. Chang, A. T.-Y. Lin, A. M.-F. Yen, et al.,Journal of infection and public health 2023 Vol. 16 Issue 1 Pages 55-63
8.許玉龍. (2022). 與新冠肺炎共存下的兒童及青少年疫苗觀點. 醫療品質雜誌, 16(4), 72-77.
9. Xing, K.; Tu, X.Y.; Liu, M.; Liang, Z.W.; Chen, J.N.; Li, J.J.; Jiang, L.G.; Xing, F.Q.; Jiang, Y. Efficacy and safety of COVID-19 vaccines: A systematic review. Zhongguo Dang Dai Er Ke Za Zhi 2021, 23, 221–228.
10.Pormohammad, A.; Zarei, M.; Ghorbani, S.; Mohammadi, M.; Razizadeh, M.H.; Turner, D.L.; Turner, R.J. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines 2021, 9, 467
11.Frenck, R.W., Jr.; Klein, N.P.; Kitchin, N.; Gurtman, A.; Absalon, J.; Lockhart, S.; Perez, J.L.; Walter, E.B.; Senders, S.; Bailey, R.; et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N. Engl. J. Med. 2021, 385, 239–250.
12.Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet 2021;397:881-91.
13.Lv M, Luo X, Shen Q, et al. Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review. Vaccines 2021;9:1102.
14.Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. The Lancet 2021;398:2093-100.
15.Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med 2022.
16.Petrelli F, Luciani A, Borgonovo K, et al. Third dose of SARS-CoV-2 vaccine: A systematic review of 30 published studies. J Med Virol 2022.
17.Arbel, R., Hammerman, A., & Netzer, D. (2023). Bivalent Boosters against Severe Omicron Infection. The New England journal of medicine, 388(18), 1726.
18.Lin, D.-Y., Xu, Y., Gu, Y., Zeng, D., Sunny, S. K., & Moore, Z. (2023). Durability of Bivalent Boosters against Omicron Subvariants. New England Journal of Medicine, 388(19), 1818-1820.
19.Lin, D.-Y., Xu, Y., Gu, Y., Zeng, D., Wheeler, B., Young, H., Sunny, S. K., & Moore, Z. (2023). Effectiveness of bivalent boosters against severe omicron infection. New England Journal of Medicine, 388(8), 764-766.
20.SAGE updates COVID-19 vaccination guidance https://www.who.int/news/item/28-03-2023-sage-updates-covid-19-vaccination-guidance
21.MacDonald, N. E. (2015). "Vaccine hesitancy: Definition, scope and determinants." Vaccine 33(34): 4161-4164.
22.World Health Organization. Ten Threats to global health in 2019.[accessed 2021 Apr 13]https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
23.Cornwall W. Officials gird for a war on vaccine misinformation. Science. 2020;369:14–19. doi: 10.1126/science.369.6499.14.
24.Wang, C.-W., et al. (2022). "A matter of trust: a qualitative comparison of the determinants of COVID-19 vaccine hesitancy in Taiwan, the United States, the Netherlands, and Haiti." Human Vaccines & Immunotherapeutics: 1-10.
25.Hause, A. M., Marquez, P., Zhang, B., Su, J. R., Myers, T. R., Gee, J., Panchanathan, S. S., Thompson, D., Shimabukuro, T. T., & Shay, D. K. (2023). Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among children aged 5–11 years—United States, October 12–January 1, 2023. Morbidity and Mortality Weekly Report, 72(2), 39.
26.Offit, P. A. (2022). Covid-19 boosters—where from here? In (Vol. 386, pp. 1661-1662): Mass Medical Soc.
27.Adams, K., Rhoads, J. P., Surie, D., Gaglani, M., Ginde, A. A., McNeal, T., Talbot, H. K., Casey, J. D., Zepeski, A., & Shapiro, N. I. (2022). Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. bmj, 379.
28.Jefferson, T., Foxlee, R., Del Mar, C., Dooley, L., Ferroni, E., Hewak, B., Prabhala, A., Nair, S., & Rivetti, A. (2008). Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. bmj, 336(7635), 77-80.
29.Wang, Chia-Wen, et al. "A matter of trust: a qualitative comparison of the determinants of COVID-19 vaccine hesitancy in Taiwan, the United States, the Netherlands, and Haiti." Human vaccines & immunotherapeutics 18.5 (2022): 2050121.
30.Johnson, A. G., Linde, L., Ali, A. R., DeSantis, A., Shi, M., Adam, C., Armstrong, B., Armstrong, B., Asbell, M., & Auche, S. (2023). COVID-19 incidence and mortality among unvaccinated and vaccinated persons aged≥ 12 years by receipt of bivalent booster doses and time since vaccination—24 US jurisdictions, October 3, 2021–December 24, 2022. Morbidity and Mortality Weekly Report, 72(6), 145.
31.Beaney, T., Clarke, J. M., Jain, V., Golestaneh, A. K., Lyons, G., Salman, D., & Majeed, A. (2020). Excess mortality: the gold standard in measuring the impact of COVID-19 worldwide? Journal of the Royal Society of Medicine, 113(9), 329-334.
-
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89816-
dc.description.abstract背景:
2019年底,由中國武漢市引發之COVID-19大流行席捲全球,已造成逾6.7億人感染及680萬人死亡,距今流行已超過三年,因空氣傳播為病毒主要傳播途徑,流行初期為阻斷傳染,多以社交距離、口罩及勤洗手等非醫療介入措施作為防疫措施,而2021年疫苗問世後,開始以接種疫苗為主要的防疫手段。然而隨著變種病毒不斷變異,各國受到Omicron變種病毒肆虐,流行從BA.1/BA.2、BA.4/BA.5、BA.2.75走到XBB.1.5。然而疫苗效益是否有效預防感染及後續中重症也成為後疫情時代重要議題。
目的:
本研究目的欲評估彰化縣疫苗施打對於預防Omicron變種病毒感染、中/重症及死亡效益。
方法:
本研究探討對象為「設籍彰化縣」人口,並自衛生福利部疾病管制署全國預防接種資訊管理系統(簡稱: NIIS系統)獲取個人疫苗接種資料,並結合彰化縣整合式篩檢資料庫,得到參加篩檢民眾資料人口學變項及疾病史等變項,分析各年齡層疫苗接種涵蓋情形,並追蹤其後續新冠肺炎感染、中重症及死亡狀態。此研究為觀察性世代追蹤研究,藉由疫苗施打與否狀態評估此族群新冠肺炎感染、中重症及死亡效益。統計方法使用羅吉斯回歸及時間相依寇斯模型進行統計分析,計算相關因子對於新冠肺炎風險程度及疫苗施打保護效益。
結果:
根據疫苗涵蓋率統計,全彰化縣疫苗未接種及僅接種一劑為13.93%、兩劑為86.07%、追加劑為74.42%,整體而言女性施打率均高於男性,0歲至5歲之幼兒、75歲以上疫苗涵蓋率相較於其他年齡層施打率低。而施打追加劑疫苗相較於未施打追加劑預防感染效益經由時間相依寇斯模型後顯示效益約為12% (Hazard Ratio: 0.883, 95% CI: 0.878-0.889)。此外,施打追加劑疫苗預防中重症(包含入ICU或到院死亡後確診)效益相較於未完整接種疫苗者相比,預防中/重症及後續死亡風險70% (Odds Ratio: 0.30, 95% CI:0.24-0.38。
討論與結論:
本研究初步探討COVID-19疫苗接種之效果,顯示疫苗接種可有效降低部分感染以及降低COVID-19發生中重症風險,可作為公共衛生對於有效遏止COVID-19造成死亡介入措施,然而接種疫苗效益可能隨時間下降,仍需後續研究深入探討。
zh_TW
dc.description.abstractBackground:
The COVID-19 pandemic, which began in late 2019 in Wuhan, China, has swept across the globe and has resulted in over 670 million infections and 6.8 million deaths. The pandemic has now lasted over three years, and as airborne transmission is the main route of transmission, early prevention measures focused on non-medical interventions such as social distancing, mask-wearing, and hand hygiene. After the introduction of vaccines in 2021, vaccination became the primary way of preventing the disease. However, as the virus continues to mutate, countries around the world have been hit hard by the Omicron variant, which has progressed from BA.1/BA.2 to BA.4/BA.5, BA.2.75, and XBB.1.5. The effectiveness of the vaccine in preventing infections and subsequent severe or critical illness has become a significant issue in the post-pandemic era.
Aims:
The objective of this study is to evaluate the effectiveness of vaccination in preventing Omicron variant infection, severe or critical illness, and death in Changhua County.
Methods:
The study population consists of individuals residing in Changhua County, and personal vaccination data was obtained from the National Immunization Information System (NIIS). The study utilized data collected from the Changhua Community-based Integrated Screening program Database, which includes demographic characteristics and medical history. The vaccination coverage rate of each age group was analyzed, and the subsequent occurrence of COVID-19 infection, severe or critical illness, and death were tracked. This study employed an observational cohort study design, and vaccine status was used to evaluate the effectiveness of vaccination in preventing COVID-19 infection, severe or critical illness, and death. Logistic regression and time-dependent Cox models were used for statistical analysis to calculate the protection provided by vaccination and the associated risk factors.
Results:
According to the statistics on vaccine coverage, the percentage of people in Changhua County who have not received the vaccine or have only received one dose is 13.93%, while those who have received two doses are 86.07%, and those who have received booster doses are 74.42%. Overall, the vaccination rate for females is higher than that of males, and the vaccine coverage rate for children aged 0-5 and those aged 75 and above is lower than that of other age groups. In addition, the effectiveness of receiving a booster vaccine compared to not receiving one, as measured by a time-dependent Cox model, is about 12% (Hazard Ratio: 0.883, 95% CI: 0.878-0.889). Furthermore, the efficacy of receiving a booster vaccine in preventing moderate-to-severe disease (including ICU admission or death after hospital admission) is 70% lower than that of those who have not completed their vaccination (Odds Ratio: 0.30, 95% CI: 0.24-0.38)
Conclusion:
This study provides preliminary evidence that COVID-19 vaccination can effectively reduce some infections and lower the risk of severe illness caused by COVID-19. This can serve as a public health intervention to effectively prevent COVID-19-related deaths. However, the effectiveness of vaccination may decrease over time, and further research is needed to explore this issue.
en
dc.description.provenanceSubmitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-22T16:14:31Z
No. of bitstreams: 0
en
dc.description.provenanceMade available in DSpace on 2023-09-22T16:14:31Z (GMT). No. of bitstreams: 0en
dc.description.tableofcontents致謝------------------------------------------------------------------------------i
中文摘要-------------------------------------------------------------------------ii
英文摘要-------------------------------------------------------------------------iv
目錄----------------------------------------------------------------------------vii
圖目錄---------------------------------------------------------------------------ix
表目錄----------------------------------------------------------------------------x
第一章 導論(Chapter1. Introduction) ----------------------------------------------1
第一節 實習單位簡介-------------------------------------------------------------1
第二節 研究背景與動機-----------------------------------------------------------2
第三節 研究問題與假設-----------------------------------------------------------3
第二章 文獻查證(Chapter 2. Literature Review) ------------------------------------4
第一節 接種新冠疫苗的重要性------------------------------------------------------4
第二節 新冠疫苗安全性及有效性----------------------------------------------------5
第三節 防疫困境與疫苗猶豫--------------------------------------------------------8
第三章 研究方法(Chapter 3. Methods) ----------------------------------------------9
第一節 研究資料來源------------------------------------------------------------9
第二節 研究設計----------------------------------------------------------------9
第三節 研究資料變項------------------------------------------------------------9
第四節 資料處理---------------------------------------------------------------10
第四章 結果(Chapter 4. Results) -------------------------------------------------12
第一節 背景資料分析------------------------------------------------------------12
第二節 疫苗預防新冠肺炎感染效益-------------------------------------------------17
第三節 新冠肺炎中重症及死亡相關風險因子及疫苗效益---------------------------------22
第五章討論(Chapter 5. Discussion) -----------------------------------------------28
第一節 疫苗接種與感染近況-------------------------------------------------------28
第二節 後疫情時代之疫苗接種策略--------------------------------------------------28
第三節 結論--------------------------------------------------------------------29
參考文獻(References)-------------------------------------------------------------30
-
dc.language.isozh_TW-
dc.title彰化縣新冠疫苗接種現況與效益相關因子探討zh_TW
dc.titleEvaluation on the current status of COVID-19 vaccination in Changhua County and related factors of effectivenessen
dc.typeThesis-
dc.date.schoolyear111-2-
dc.description.degree碩士-
dc.contributor.oralexamcommittee葉彥伯;賴昭智zh_TW
dc.contributor.oralexamcommitteeYen-Po Yeh;Chao-Chih Laien
dc.subject.keywordCOVID-19疫情,疫苗接種,精準防疫,整合式篩檢,預防中重症,zh_TW
dc.subject.keywordCOVID-19 pandemic,vaccination,precise epidemic prevention,,integrated screening,prevention of moderate to severe disease,en
dc.relation.page32-
dc.identifier.doi10.6342/NTU202302557-
dc.rights.note未授權-
dc.date.accepted2023-08-08-
dc.contributor.author-college公共衛生學院-
dc.contributor.author-dept公共衛生碩士學位學程-
顯示於系所單位:公共衛生碩士學位學程

文件中的檔案:
檔案 大小格式 
ntu-111-2.pdf
  目前未授權公開取用
1.17 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved